About CSL Behring Investigator-Initiated Studies Program

CSL Behring is committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in the support for investigator-initiated studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they are designed to treat. CSL Behring also supports innovative clinical and basic science studies that address important medical and scientific questions related to our therapeutic areas of interest:

  • Immunodeficiency
  • Hemophilia Disorders
  • Immune-mediated Neuromuscular Disorders
  • Acquired & Oral Anticoagulant-Associated Bleeding
  • Hereditary Angioedema (HAE)

The CSL Behring IIS program is open to US physicians, researchers and institutions interested in conducting their own research. For those outside the US, contact your local CSL Behring Medical Affairs representative. We receive many requests for support and carefully evaluate each one. Priority is given to proposals that align with our interests.

Disclaimer: all materials submitted as IIS concepts must be nonconfidential. By submitting an IIS concept, you acknowledge that CSL Behring is under no obligation of confidentiality with respect to materials submitted.

Our Request Requirements have recently changed. Please take a moment to review them.